Top

Published in:

Open Access 01-06-2018 | Review Article

Optimal treatment of patients with NSTE-ACS in the Dutch health care system

Authors: J. P. van Kuijk, J. M. ten Berg

Published in: Netherlands Heart Journal | Issue 6/2018

Abstract

In the current daily practice of acute coronary syndromes, patients experiencing non-ST-elevation acute coronary syndrome (NSTE-ACS) represent the majority of this population. In these patients it is of utmost importance to estimate both ischaemic and bleeding risk, with subsequent, and preferably tailored pharmacological and, if indicated, invasive treatment. In this paper we describe the several risk scores and evaluate which are most applicable to the Dutch health-care system. Furthermore, we provide an overview of the recommended pharmacological treatment in keeping with the European Society of Cardiology guidelines. An important topic of this paper is how to decide between early or delayed invasive strategies. We describe the recommendations of the European Society of Cardiology and evaluate to which level these should be applied to the Dutch health-care system.

Diercks DB, Peacock WF, Hiestand BC, et al. Frequency and consequences of recording an electrocardiogram 〉10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADA initiative). Am J Cardiol. 2006;97:437–42.CrossRefPubMed

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.CrossRefPubMed

Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin. Arch Intern Med. 2012;172:1211–8.CrossRefPubMed

Zhelev Z, Hyde C, Youngman E, et al. Diagnostic accuracy of single baseline measurement of Elecsys troponin T high-sensitivity assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ. 2015;350:h15.CrossRefPubMedPubMedCentral

Rubini Gimenez M, Twerenbold R, Jaeger C, et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. Am J Med. 2015;128:861–70.CrossRefPubMed

Roffi M, Patrono C, Collet J‑P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;14:267–315.CrossRef

Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707–13.CrossRefPubMed

Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53.CrossRefPubMed

Reichlin T, Twerenbold R, Reiter M, et al. Introduction of high-sensitivity troponin assays; impact on myocardial infarction incidence and prognosis. Am J Med. 2012;125:1205–13.CrossRefPubMed

10.

Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4:e4425.CrossRefPubMedPubMedCentral

11.

Bawamia B, Mehran R, Qiu W, et al. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am Heart J. 2013;165:441–50.CrossRefPubMed

12.

Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes; insights form GUSTO-IIb and PURSUIT. Am Heart J. 2004;148:62–71.CrossRefPubMed

13.

Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32:1854–64.CrossRefPubMed

14.

Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST segment elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding score. Circulation. 2009;119:1873–82.CrossRefPubMedPubMedCentral

15.

Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55:2556–66.CrossRefPubMed

16.

Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2012;1:222–31.CrossRefPubMedPubMedCentral

17.

Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA. 1988;260:2088–93.CrossRefPubMed

18.

Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy; results from the American College of Cardiology’s NCDR. Am Heart J. 2011;161:864–70.CrossRefPubMed

19.

The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–30.CrossRef

20.

Jr Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Eng J Med. 1983;309:396–403.CrossRef

21.

Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–11.CrossRefPubMed

22.

Antithrombotic Trialists’Collaboration.. Collaborative meat-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRef

23.

Yusuf F, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med. 2001;345:494–502.CrossRef

24.

Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215–23.CrossRefPubMed

25.

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2007;357:2001–15.CrossRef

26.

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes. N Eng J Med. 2009;361:1045–57.CrossRef

27.

Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382:1981–92.CrossRefPubMed

28.

Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.CrossRefPubMed

29.

Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Eng J Med. 2013;369:999–1010.CrossRef

30.

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.CrossRefPubMed

31.

Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient dataset from clinical trials. Lancet. 2017;389:1025–34.CrossRefPubMed

32.

Yeh RW, Cesemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–79.CrossRefPubMedPubMedCentral

33.

Koskinas KC, Raber L, Zanchin T. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(5):e2053.CrossRefPubMed

34.

Eikelboom JW, Anand SS, Malmberg K, et al. Unfractioned heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–42.CrossRefPubMed

35.

Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.CrossRefPubMedPubMedCentral

36.

Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–8.CrossRefPubMed

37.

Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Eng J Med. 2006;354:1464–76.CrossRef

38.

Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48:1319–25.CrossRefPubMed

39.

O’Donoghue M, Boden WE, Braunwal E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300:71–80.CrossRefPubMed

40.

Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010;55:2435–45.CrossRefPubMed

41.

Navarese EP, Gurbel PA, Andreotti F, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med. 2013;158:261–70.CrossRefPubMed

42.

Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Eng J Med. 2009;360:2165–75.CrossRef

43.

Sorajja P, Gersh BJ, Cox DA, et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management; analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage StratgY) trial. J Am Coll Cardiol. 2015;55:1416–24.CrossRef

44.

van’t Hof A, ten Berg JM, Jukema JW, et al. ESC_NSTEACS_AMENDEMENT_ACS werkgroep. Feb 2016, www.nvvc.nl. Accessed 01.02.2016

Title: Optimal treatment of patients with NSTE-ACS in the Dutch health care system
Authors: J. P. van Kuijk
J. M. ten Berg
Publication date: 01-06-2018
Publisher: Bohn Stafleu van Loghum
Published in: Netherlands Heart Journal / Issue 6/2018
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI: https://doi.org/10.1007/s12471-018-1114-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Optimal treatment of patients with NSTE-ACS in the Dutch health care system

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Optimal duration of dual antiplatelet therapy for coronary artery disease

Delayed neointimal healing pattern after bioresorbable scaffold implantation

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation

Cough up your lungs

Cough up your lungs

Anticoagulation and antiplatelet therapy in acute coronary syndromes: choosing between the Scylla of bleeding and the Charybdis of ischaemic events

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page